Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1624-1630

  De Vuyst, H ^a   Mugo, N R ^b   Chung, M H ^c   McKenzie, K P ^c   Nyongesa Malava, E ^c   Tenet, V ^a   Njoroge, J W ^c   Sakr, S R ^d   Meijer, Cjl M ^e   Snijders, P J F ^e   Rana, F S ^f   Franceschi, S ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KENYATTA NATIONAL HOSPITAL   (Kenya)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Internal Medicine and Critical care Department   (Kenya)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f AGA KHAN UNIVERSITY   (Kenya)

Author keywords

Africa; cervical neoplasia; combination antiretroviral therapy; HIV; human papillomavirus

Indexed keywords

ADULT; ARTICLE; BIOPSY; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KENYA; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84867897226     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.441     Document Type: Article

References (38)

1. Bratcher LF, Sahasrabuddhe VV (2010) The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 5: 8
2. Brower V (2011) AIDS-related cancers increase in Africa. J Natl Cancer Inst 103: 918-919
3. Chung MH, McKenzie KP, De Vuyst H, Pamnani R, Rana F, Njoroge JW, John-Steward G, Richardson B, Sakr S, Mugo NR (2011a) Comparing visual inspection with acetic acid, high-risk HPV testing, and Pap smear to colposcopic biopsy among HIV+ women. 18th Conference on Retroviruses and Opportunistic Infections; Boston, USA; 27 February-2 March 2011. Presentation 41 [Abstract]
4. Chung MH, McKenzie KP, Richardson BA, John-Stewart GC, Coombs RW, De Vuyst H, Njoroge JW, Nyongesa-Malava E, Sakr SR, Mugo NR (2011b) Cervical HIV-1 RNA shedding after cryotherapy among HIVpositive women with cervical intraepithelial neoplasia stage 2 or 3. AIDS 25: 1915-1919
5. Clarke MA, Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Wacholder S, Burk RD, Schiffman M (2011) A population-based crosssectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. Infect Agent Cancer 6: 12
6. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998
7. Clifford GM, Goncalves MA, Franceschi S (2006) Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20: 2337-2344
8. Corbeau P, Reynes J (2011) Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 117: 5582-5590
9. De Vuyst H, Lillo F, Broutet N, Smith JS (2008) HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17: 545-554
10. De Vuyst H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S, Temmerman M, Franceschi S, Lillo F (2010) The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes Control 21: 2309-2313
11. Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R, Myer L (2008) Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 111: 1380-1387
12. Djigma FW, Ouedraogo C, Karou DS, Sagna T, Bisseye C, Zeba M, Ouermi D, Gnoula C, Pietra V, Ghilat-Avoid-Belem NW, Sanogo K, Sempore J, Pignatelli S, Ferri AM, Nikiema JB, Simpore J (2011) Prevalence and genotype characterization of human papillomaviruses among HIVseropositive in Ouagadougou, Burkina Faso. Acta Trop 117: 202-206
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer: Lyon, France. Available from http://globocan.iarc.fr
14. Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, Lewis DA, Williamson AL, Allan B, Williams S, Rinas A, Levin S, Smith JS (2010) Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 21: 433-443
15. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O (2010) Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 103: 416-422
16. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M (2012) The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-andtreat strategies. Int J Cancer 130: 2111-2117
17. Giorgi-Rossi P, Franceschi S, Ronco G (2012) HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer 130: 1387-1394
18. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM (2012) Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (in press)
19. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ (2000) Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the agerelated patterns for high-risk and low-risk types. Int J Cancer 87: 221-227
20. Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJ, Meijer CJ, Franceschi S (2009) HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 101: 202-208
21. Kitchener H, Nelson L, Adams J, Mesher D, Sasieni P, Cubie H, Moore C, Heard I, Agarossi A, Casolati E, Denny L, Bradbeer C, Lyons F, Beattie G, Niemiec T (2007) Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 121: 2484-2491
22. Kuhn L, Wang C, Tsai WY, Wright TC, Denny L (2010) Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 24: 2553-2561
23. Luff RD (1992) The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda workshop. Am J Clin Pathol 98: 152-154
24. Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH, Levine AM, Wright RL, Colie C, D'Souza G, Massad LS, Strickler HD (2010) Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 201: 681-690
25. Ojoo S (2007) Kenya National Clinical Manual for ART Providers: A Concise and Practical Guide to ART Provision. 2nd edition. National AIDS and STI Control Program (NASCOP): Nairobi, 70 p
26. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A (2009) The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 113: 26-31
27. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13: 78-88
28. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249-257
29. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Engl J Med 360: 1385-1394
30. Schiffman M, Clifford G, Buonaguro FM (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 4: 8
31. Shrestha S, Sudenga SL, Smith JS, Bachmann LH, Wilson CM, Kempf MC (2010) The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIVpositive adolescents. BMC Infect Dis 10: 295
32. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Mutimura E, Cajigas A, Bigirimani V, Cai X, Rwamwejo J, Vuolo M, Cohen M, Castle PE (2009) Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 199: 1851-1861
33. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X, Schlecht NF, Melnick S, Palefsky JM (2005) Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97: 577-586
34. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, Bacon M, Schuman P, Levine AM, Durante AJ, Gange S, Melnick S, Burk RD (2003) Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95: 1062-1071
35. Tobian AA, Kong X, Wawer MJ, Kigozi G, Gravitt PE, Serwadda D, Eaton KP, Nalugoda F, Quinn TC, Gray RH (2011) Circumcision of HIVinfected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. Lancet Infect Dis 11: 604-612
36. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ (2002) GP5+6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40: 779-787
37. Vanni T, Luz PM, Grinsztejn B, Veloso VG, Foss A, Mesa-Frias M, Legood R (2012) Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country. Int J Cancer 131: E96-104
38. WHO (2011) Global HIV/AIDS response: Progress report 2011. Key facts on HIV epidemic and progress in regions and countries in 2010, sub-Saharan Africa. Available at http://www.who.int/hiv/pub/progress-report2011/regional-facts/en/ index.html. Accessed August 2012